Table 3. Univariate analysis of different clinicopathological factors for overall survival (OS) and disease-free survival (DFS).

		OS (months)			DFS (months)
	n	Median (s.e.b)	95% CIa	P-value	Median (s.e.)	95% CI	P-value
Gender
Male	241	77 (13)	51–103		Nr	—
female	38	Nrc	—	0.2677	84 (37)	12–156	0.8626
Histiotype
Adenocarcinoma	93	59 (10)	40–78		Nr	—
Squamous	128	87 (11)	66–108	0.6150	Nr	—	0.4168
Large cell	42	Nr	—	0.8902	Nr	—	0.8088
other	16	Nr	—	0.7518	71 (44)	0–156	0.9604
Localisation
Left	122	69 (12)	46–92		84 (30)	26–124
right	157	90 (11)	65–111	0.1260	Nr	—	0.1295
Type of operation
(Bi)lobectomy	192	94 (12)	70–118		Nr	—
Pneumonectomy	87	35 (7)	21–49	0.0004	22 (6)	10–34	0.0005
T-status
T1	89	94 (15)	64–124		102 (17)	68–136
T2	147	72 (15)	44–100	0.1050	Nr	—	0.0646
T3	20	Nr	—	0.8880	Nr	—	0.2792
T4	23	37 (9)	19–55	0.0151	18 (2)	15–21	0.0011
N-status
N0	198	102 (10)	83–121		Nr	—
N1	64	39 (8)	23–55	0.0002	27 (12)	3–51	0.0009
N2	17	29 (8)	13–45	0.0001	12 (3)	5–19	<0.0001
Stage
St IA	77	94 (15)	65–123		Nr	—
St IB	90	90 (10)	70–110	0.6234	Nr	—	0.3330
St IIA	12	46 (2)	41–51	0.0623	22 (21)	0–63	0.0135
St IIB	60	58 (24)	12–104	0.0098	71 (28)	17–125	0.0055
St IIIA	17	29 (7)	14–44	0.0001	12 (7)	0–25	<0.0001
St IIIB	23	37 (9)	19–55	0.0045	18 (2)	15–21	0.0001
Radiotherapy
No	227	90 (11)	68–112		Nr	—
received	52	33 (10)	14–52	0.0074	21 (4)	14–28	0.0003
Growth pattern
Destructive	196	96 (13)	71–121		Nr	—
Papillary	38	48 (10)	28–68	0.1640	Nr	—	0.3039
Alveolar	45	59 (25)	10–108	0.0130	22 (11)	0–44	0.0070

^a95% CI=95% confidence interval.

^bs.e.=standard error.

^cNot reached.